Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice

Leukemia Research

Volumn 39, Issue 11, 2015, Pages 1154-1158

  Ellis, Martin H ^a,b   Lavi, Noa ^c,d   Mishchenko, Elena ^e   Dally, Najib ^f   Lavie, David ^g   Courevitch, Anna ^h   Gutwein, Odit ⁱ   Bulvik, Shlomo ^j   Braester, Andrei ^k   Chubar, Evgeni ^l   Tavor, Sigal ^m   Duek, Adrian ⁿ   Kirgner, Ilya ^b,o   Koren Michowitz, Maya ^b,n  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Rambam Health Care Campus ^*  (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

^f Rebecca Sieff Government Hospital   (Israel)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁱ ASSAF HAROFEH MEDICAL CENTER   (Israel)

^j LANIADO HOSPITAL   (Israel)

^k WESTERN GALILEE HOSPITAL   (Israel)

^l HAEMEK MEDICAL CENTER   (Israel)

^m Maccabi Health Organization   (Israel)

ⁿ SHEBA MEDICAL CENTER   (Israel)

^o TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

more..

Author keywords

Myelofibrosis; Population study; Ruxolitinib

Indexed keywords

RUXOLITINIB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; PHASE 3 CLINICAL TRIAL (TOPIC); POST ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS; POST POLYCYTHEMIA VERA MYELOFIBROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 84955723723     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.08.003     Document Type: Article

References (19)

1. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
2. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
3. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
4. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
5. Mascarenhas J., Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin. Cancer Res. 2012, 18:3008-3014.
6. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 2012, 366:787-798.
7. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 2012, 366:799-807.
8. Verstovsek S., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Kadia T., et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120:1202-1209.
9. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica 2015, 23:115840.
10. Abdelrahman R.A., Begna K.H., Al-Kali A., Hogan W.J., Litzow M.R., Tefferi A. Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia 2014, 25:286.
11. Tefferi A., Litzow M.R., Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N. Engl. J. Med. 2011, 365:1455-1457.
12. Mesa R.A., Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs). Cancer 2007, 109:68-76.
13. Tefferi A., Lasho T.L., Jimma T., Finke C.M., Gangat N., Vaidya R., et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin. Proc. 2012, 87:25-33.
14. Mesa R.A., Kantarjian H., Tefferi A., Dueck A., Levy R., Vaddi K., et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011, 117:4869-4877.
15. Tefferi A., Cervantes F., Mesa R., Passamonti F., Verstovsek S., Vannucchi A.M., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013, 122:1395-1398.
16. Cervantes F., Vannucchi A.M., Kiladjian J.J., Al-Ali H.K., Sirulnik A., Stalbovskaya V., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013, 122:4047-4053.
17. Martino B., le Coutre P., Griesshammer M., Illmer T., Schlag R., Waller C.F., et al. Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update 2014.
18. Jung C.W., Shih L.Y., Xiao Z., Jie J., Hou H.A., Du X., et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk. Lymphoma 2014, 1-8.
19. Mesa R.A., Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J. Hematol. Oncol. 2013, 6:79.